Admin

Goldman Sachs Comments on Marvell’s Quarterly Report: Perfectly Matches Wall Street Expectations—Keep a Close Eye on These Three Key Areas Next!

Goldman Sachs Comments on Marvell’s Quarterly Report: Perfectly Matches Wall Street Expectations—Keep a Close Eye on These Three Key Areas Next!

Marvell Technology has delivered a quarterly report closely matching Wall Street's expectations, and boosted market confidence with guidance for next quarter that exceeded forecasts. Management simultaneously hinted at raising full-year guidance for FY27/28. Goldman Sachs believes the stock price is likely to rise moderately in the short
Admin
Five years later, knocking on the door again: Unprofitable pharmaceutical company Haihe Biopharma restarts STAR Market IPO with new standards

Five years later, knocking on the door again: Unprofitable pharmaceutical company Haihe Biopharma restarts STAR Market IPO with new standards

``` On May 28, Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. (“Haihe Pharma”) submitted its Sci-Tech Innovation Board (STAR Market) IPO prospectus to the Shanghai Stock Exchange and received acceptance. This innovative anti-tumor drug company, whose actual controller is Academician Ding Jian of the Chinese Academy of Engineering, is making
Admin